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1. Introduction 
Matrix metalloproteinases (MMPs) were first described by Gross fifty years ago. They are a 
family of zinc-dependent endopeptidases. They comprise a group of 25 enzymes. 
Metalloproteinases were first described as proteases degrading extracellular matrix (ECM) 
proteins such as collagens, elastin, proteoglycans and laminins, hence they were named 
matrix meatalloproteinases. MMPs were divided according to their substrate specificity into 
collagenases, gelatinases, stromolysins and matrilysins. This classification was later replaced 
by numbering the enzymes according to the chronology of their identification. 
Metalloproteinases are also called metalloproteases. 
Four metalloproteases (MMP-14, MMP-15, MMP-16 and MMP-24) have a transmembrane 
and cytosolic domains. They constitute a subgroup of membrane-type metalloproteases 
(MT-MMPs) [1, 2]. 
2. Physiological role of metalloproteinases 
MMP-1 (collagenase 1) hydrolyzes collagen types I, II, III, VII, VIII, X and XI, as well as 
gelatin, fibronectin, vitronectin, laminin, tenascin, aggrecan, links protein, myelin basic 
protein and versican. MMP-2 (gellatinase) degrades collagen types I, II, III, IV, V, VII, X and 
XI, gelatin, elastin, fibronectin, vitronectin, laminin, entactin, tenascin, SPARC and aggrecan, 
links protein, galectin-3, versican, decanin and myelin basic protein. One of the most 
important differences between theses two metalloproteinases is the possibility of the 
hydrolysis of elastin and collagen type IV by MMP-2, but not by MMP-1. Researches have 
also focused their interest on MMP-9 which can degrade collagen types IV, V, VII, X and 
XIV, fibronectin, laminin, nidogen, proteoglycan link protein and versican. 
For a long time metalloproteinases have been vied solely as enzymes of matrix proteins 
breakdown. Results of researches performed in recent years indicate that there is a group of 
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non-matrix proteins which can be substrates for various MMPs. Metalloproteinases are 
involved in the activation of latent forms of effective proteins. For example, MMP-2, MMP-3 
and MMP-9 can activate interleukin 1 (IL-1). They can also act on active cytokines, IL-1 
undergoes subsequent degradation catalyzed by MMP-3. Metalloproteinases can alter cell 
surface proteins such as receptors and act on microbial peptides. 
Metalloproteinases are not indiscriminately released by cells. They are secreted to or 
anchored to cell membrane. MT-MMPs have a specific transmembrane domain placing them 
in a certain position. Other metalloproteinases can be bound by specific cell-MMP 
interactions. This phenomenon allows an exact localization of their proteolytic activity [1,2]. 
3. Activation of metalloproteinases 
Metalloproteinases are encoded as inactive proenzymes, zymogens. They undergo 
proteolytic activation. This process can take place either intracellulary or extracellulary. One 
third of MMPs are activated by intracellular serin protease, furin. This process takes place in 
trans-Golgi network. A number of MMPs has a cleavage site for other metalloproteinases. 
MMP-3 activates proMMP-1 and pro-MMP-7. Some metalloproteinases have been described 
to be activated by kallikrein or plasmin. 
In vivo studies indicate that reactive oxygen species (ROS) generated by neutrophils can both 
activate and subsequently inactivate MMPs. Hypochlorus acid (HClO) generated by 
neutrophil myeloperoxidase and hydroxyl radicals can activate proMMP-1, proMMP-7 and 
proMMP-9, whereas peroxynitrate can activate proenzymes of MMP-1, MMP-2 and MMP-9. 
This process enables a control of burst of proteolytic activity within an inflammatory setting. 
Like some other proteases, activity of MMPs is controlled also by two other mechanisms, 
regulation of gene expression and specific inhibitors. MMP-2 is constitutively expressed and 
regulation of its activity occurs by either activation or inhibition. Expression of a number of 
metalloproteinases is up-regulated during various pathological conditions. Among them 
inflammation is the most studied setting. MMPs are inhibited by α-2 macroglobulin and 
tissue inhibitors of metalloproteinases (TIMPs). There are four TIMPs. Their secretion is also 
regulated and represents another point in a network of control of the activity of 
metalloproteinases. TIMP-3 is primarily bond to ECM and allows a regulation of MMPs’ 
activity in the very site of their action. The network of the control of the activity of 
metalloproteinases is complex and very precise. Sometimes TIMP interacts with proMMP 
and inactivate other MMP, e.g. a complex of TIMP-1 and proMMP-9 inactivates MMP-3. 
Protection from MMP degradation represents the next step in this sophisticated network of 
diverse interactions. Neutrophil gelatinase-associated lipocalin (NGAL) bounds to MMP-9 
protecting this metalloproteinase from its degradation [1,2]. 
4. Localisation of metalloproteinases in a vascular wall  
Metalloproteinases can be detected in all three layers of a vascular wall. Endothelium can 
produce MMP-1 and MMP-2. Smooth muscle cells (SMC) of both intima and media are the 
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next source of MMPs. They can secrete MMP-2 and MMP-9. SMC can also produce TIMP-1 
and TIMP-2. Adventitia is the layer where MMP-9 can be synthesized. Apart from these 
most studied metalloproteinases some other MMPs can be detected in a vascular wall: MT1-
MMP, MMP-3, MMP-8, MMP-10, MMP-12 and MMP-13. Metalloproteinases are found not 
only in a wall of arterial wall, but in veins as well.  
The balance between the expression of MMPs and TIMPs plays a vital role in preserving the 
proper and health state of the vascular wall. This equilibrium between activation and 
inactivation of MMPs is a part of a balance between synthesis and degradation of collagen 
and elastin, two proteins which have various properties and functions in the arterial wall. 
Both proteins are crucial for a proper function of the arterial wall. An interruption of these 
two balances may lead to a development of various vascular pathologies including 
atherosclerosis, formation of aneurysm and inflammation [3-5]. 
5. Metalloproteinases and aneurysms 
The most studied aneurysm is abdominal aortic aneurysm (AAA), far less research has been 
focused on aneurysms of cerebral arteries and thoracic aortic aneurysm. All aneurysms are 
characterized by the destruction of the structural integrity of the extracellular matrix 
proteins, mainly collagens and elastin. MMPs involved in this pathology can origin both 
from the cells that physiologically constitute the arterial wall and are stimulated to secrete 
MMPs, i.e. endothelium, SMC and cells that infiltrate the arterial wall in a response to 
various stimuli [1, 3, 6-9]. 
Many scientists points out that cells constituting an inflammatory infiltrate are the major 
source of metalloproteinases involved in the development of aneurysms. Studies of samples 
derived from patients undergoing surgery for AAA demonstrated that macropgages from 
the inflammatory infiltrate can express MMP-1, MMP-2, MMP-3, MMP-9 and MT-1MMP. 
Metalloproteinase-2 was often detected in cells physiologically constituting the arterial wall, 
but was absent in macrophages within aneurysms. The pathogenesis of AAA and 
aneurysms of cerebral arteries differs as these vessels present different types of arteries and 
there are some differences in the physical characteristic of blood flow in them. Recent 
experimental studies carried on animals confirmed the role of macrophage infiltration in the 
formation of intracranial aneurysms. A degranulation of mast cells induces the expression 
and activation of MMP-2 and MMP-9. Inhibitors of mast cell degranulation inhibited the 
development of cerebral aneurysms in experimental rats [10, 11]. 
Human studies confirmed that the expression of metalloproteinases within the AAA is 
greater than in other sites, remote from the dissection. Nishimura et al. observed a different 
profile of MMP activation in small size abdominal aortic aneurysms, less than 45 mm and 
large size AAA with diameter exceeding 45 mm. In small size AAA MMP-2 and MMP-9 
presented greater gene expression whereas in large size AAA membrane type-1 
metalloproteinase and MMP-9 had greater expression. The same study demonstrated also 
differences in the distribution of the metalloproteinases in the arterial wall. MMP-2 was 
detected mainly in the intima, whereas MMP-9 was present both in intima and adventitia. 
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Nishimura et al. also observed a significant correlation of the expression of MMP-2 and 
MMP-9 and between each of these metalloproteinases and TIMP-1 [6]. 
The degeneration of collagen and elastin leading to the development of aneurysms is a 
multifactorial process. Various factors may take part in the stimulation of both cells 
constituting the arterial wall and cells infiltrating it to produce MMPs. Aortic wall is 
subjected to cyclic stretching because of pulsative blood flow which is a normal 
physiological condition. AAA is often accompanied by an intraluminal thrombus. It causes 
that some cells within the aneurysm may be subjected to hypoxia. Experimental study of 
Oya et al. revealed that macrophages cultured in conditions subjected to cyclic stretching 
under normoxia and hypoxia which simulated the pulsative blood flow and hypoxia due to 
thrombus presented an increased MMP-9 production. These macrophages produced 
interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) leading to increased apoptosis of 
vascular smooth muscle cells. Hypoxia was also demonstrated to augment the expression of 
MMP-1, MT-1 MMP, MMP-2, MMP-7 and MMP-9 in SMC derived from human aorta [12, 
13].  
Nowadays many scientists focus their research on finding new factors which may augment 
the secretion of metalloproteinases by the cells present in aneurysms. Experimental studies 
confirmed that stenosis resulting in a turbulent blood flow can be the next factor increasing 
expression of MMP-2 and MMP-9 within abdominal aortic aneurysm. Interesting results 
were obtained by Stolle et al. Mice exposed to cigarette smoke and angiotensin II treatment 
had increased the incidence of AAA and higher gene expression of MMP-2, MMP-3, MMP-
8, MMP-9 and MMP-12 in aorta and increased proteolytic activity of two most investigated 
metalloproteinaes, MMP-2 and MMP-9. Although each of this two factors alone induced 
minor changes, their combination accelerated the pathologic process. Exposure of the 
arterial wall to an increased concentration of angiotensin II represents conditions that may 
be observed in patients with arterial hypertension. This experiment demonstrates that 
coexistance of arterial hypertension and smoking augments the risk of a development of 
aneurysm [14, 15]. 
Studies of Zhang et al. demonstrated that human AAA tissues had elevated levels of 
advanced glycation end products (AGEs) and their receptor (RAGE). In experimental model 
this group of researchers observed that AGEs induce the production of MMP-9 by 
macrophages. An increased serum concentration of AGEs accompanies poorly controlled 
diabetes mellitus. These results indicate that such patients may be at a greater risk of a 
development of AAA [16]. 
Abdominal aortic aneurysm is characterized not only by the destruction of its structural 
integrity of the extracellular matrix protein and inflammatory infiltrate but also by 
intensive neovascularisation. These new blood vessels developing inside the arterial wall 
in a place of growing aneurysm are the next source of metalloproteinases degrading ECM. 
Immature neovessels express MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9 and 
MMP-12 [8]. 
 
The Role of Metalloproteinases in the Development of Aneurysm 69 
Polish scientists have observed that the intraluminal thrombus occurring within AAA may 
modulate the activity of MMP-8, MMP-9, neutrophil elastase and TIMP-1. Specimens from 
patients with thin, less than 10 mm, thrombus-covered wall of AAA presented significantly 
higher activity of 3 evaluated metalloproteinases and lower TIMP-1 concentration than 
thick, exceeding 25 mm, thrombus-covered wall. The intraluminal thrombus may exert its 
pathological effect through trapping erythrocyte and neutrophils and monocytes. The exact 
mechanism of activation of MMP in these conditions has not been fully elucidated. Scientists 
consider various factors activating metalloproteinases, such as hypoxia caused by reduced 
blood flow or oxidative stress in trapped blood cells. This aspect needs further evaluation 
[17]. 
Japanese researchers compared the activity of MMP-2 and MMP-9 in ruptured and 
unruptured middle cerebral artery dissections obtained during neurosurgery in the same 
patient. Both metalloproteinases presented greater expression in the ruptured dissection 
[9]. 
6. Possible diagnostic markers 
The results of scientific researches discussed so far concern the evaluation of either 
expression or activity of MMPs in the tissue obtained from aneurysms in humans or 
experimental animals. These measurements have the scientific importance but cannot serve 
as a diagnostic marker. A growing interest is focused on finding circulating predictors of 
risk of the development of aneurysm or plasma markers of existing, yet undiagnosed 
aneurysm. Plasma levels of MMPs are of great interest. MMP-2 and MMP-9 are the 
candidates for such markers. Polish researchers observed significantly higher plasma 
concentration of MMP-9 in patients with AAA and thin intraluminal thrombus than in 
patients with abdominal aortic aneurysm and thick thrombus. Hellenthal et al. points out 
that plasma level of MMP-9 may serve as a marker discriminating patients with and without 
endoleak within AAA [18-20].  
Several polymorphisms of metalloproteinases have been discovered. Their role in the 
development of AAA is being studied. The polymorphisms of MMP-2 (1306C/T), MMP-3 
(5A/6A) and MMP-13 (77A/G) may contribute to the pathogenesis of AAA. The studies of 
circulating markers of aneurysms give promising results but further research is still required 
[21]. 
7. Visualisation of metalloproteinases in aneurysm 
Several studies have been aimed at imaging of matrix metalloproteinases and quantifying 
the inflammatory process that drives abdominal aortic aneurysm development. American 
scientists developed the MMP-activated probe, MMP Sense 18-20 (VisEn Medical, Woburn, 
USA) that was used for the in vivo and ex vivo macroscopic scale imaging. This method 
based on fluorochromes may be used intravascularly. A new magnetic resonance imaging 
contrast agent, P947, has been tested for its capabilities of targeting MMPs in vivo in 
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expanding experimental AAA. This method allows the detection of MMP activity within the 
inflammatory infiltrate within AAA and may become a potential non-invasive method to 
detect AAA at a high risk of rupture [22, 23]. 
8. Possibilities of pharmacological modulation of metalloproteinases 
activity 
Patients with a high activity of MMPs within the aneurysm are at increased risk of its 
rupture leading to serious clinical consequences including death. It is of a great importance 
to find agents which can inhibit MMPs activity and reduce this risk. 
Doxycycline, a tetracycline antibiotic, is a known inhibitor of metalloproteinases activity 
with a growing body of evidence of its beneficial effects observed in animal studies. 
However data from human studies comprising 6 controlled trials and 2 cohort studies gave 
conflicting results. The safety of long term use of doxycycline needs evaluation [24]. 
Statins are a well known group of drugs lowering plasma cholesterol level used to reduce 
the risk of a coronary heart disease. They have a pleiotropic mode of action reducing the 
progress of atherosclerosis. Experimental studies indicate that simvastatin can reduce the 
activity of MMP-2 and MMP-9 in AAA and suppress the development and expansion of 
abdominal aortic aneurysm. A study performed on samples derived from patients receiving 
atorvastatin and undergoing surgical treatment for AAA gave promising results 
demonstrating a significantly reduced activity of MMP-13. Another study with short term, 4 
weeks, administration of atorvastatin preceding the operation did not show any differences 
in the activity of MMP-2, MMP-8, MMP-9, TIMP-1 or TIMP-2. These data indicate that 
statins may require a long term use to develop their beneficial influence on MMPs’ activity 
[25-27].  
Drugs which are administered for a long time focus the scientists’ interest. Anti-
hypertensive drugs have been studied in this aspect. Calcium channel blocker, azelnidipine, 
decreased the activity of MMP-2 and MMP-9. The similar influence of angiotensin II 
receptor blockers, olmesartan and losartan, was observed. The latter was also shown to act 
synergistically with doxycycline. Perindopril, an angiotensin converting enzyme inhibitor, is 
known as an anti-hypertensive agent with an ability to affect vascular wall remodeling. In 
an experimental study perindopril significantly reduced the activity of MMP-2 and MMP-9. 
In animal studies the activity of MMP-2 and MMP-9 were also decreased by edaravone, a 
scavenger of reactive oxygen species, resveratrol, a plant derived polyphenolic compound. 
Two inhibitors of cyclic adenosine monophosphate phosphodiesterase (PDE) were also 
shown to inhibit the activity of metalloproteinases. Cilostazol, the inhibitor of PDE-3 
decreased the activity of MMP-2 and MMP-9, whereas ibudilast, which predominantly 
blocked PDE-4, decreased the expression of MMP-9 [28-37]. 
Although the experimental studies indicate that various drugs can reduce the expression 
and activity of metalloproteinases, their potential use in humans to protect from AAA or 
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inhibit its development requires further studies. Their efficacy and safety of a long term 
administration must be proven. 
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